AOD-9604 in Dagbao I — Fat Loss Peptide Research Guide
AOD-9604 research guide for Dagbao I. HGH fragment studied for fat metabolism — covers mechanism, purity standards, COA verification, and how to source AOD-9604.
Unlike common nutraceuticals stocked in every health store, AOD-9604 moves through a dedicated online market that Dagbao I residents reach through online vendors. What this means for Dagbao I researchers is that geography is secondary to your ability to assess COA data — and those verification methods are available to every researcher. Separating properly characterised AOD-9604 from the rest of the market comes down to three things: an HPLC chromatogram showing ≥98% purity, mass spec data establishing the correct molecular weight, and a batch-specific endotoxin panel. Use this guide to verify vendor quality systematically — the framework here work regardless of your location.
The Science Behind AOD-9604
CJC-1295 with DAC (Drug Affinity Complex) is a GHRH analogue with an extended half-life achieved through DAC technology that enables covalent binding to albumin. This modification extends the half-life from minutes (for native GHRH) to approximately 6-8 days, creating a sustained elevation in basal GH levels rather than the pulsatile pattern produced by GHRP compounds. This pharmacokinetic distinction is significant for research design: AOD-9604 based on CJC-1295 with DAC produces a different GH secretion pattern than GHRP compounds, with different downstream effects on IGF-1 and protein synthesis. Researchers in Dagbao I comparing compounds in this class should account for these pharmacokinetic differences in their experimental design.
How to Source AOD-9604 — Vendor Guide
The first step for any Dagbao I researcher sourcing AOD-9604 is locating suppliers that experienced researchers actively recommend — search results alone are too heavily influenced by marketing spend. The HPLC chromatogram is the most important document in the COA: it should show a clear dominant peak representing AOD-9604, with small or absent impurity peaks representing impurities — purity should be at or above 98%. Positive vendor signals beyond COA quality: multi-year operating history, customer service that can discuss analytical methods, and shipping with desiccant and appropriate cold protection. Bacteriostatic water is the standard reconstitution medium for AOD-9604 — it contains 0.9% benzyl alcohol that inhibits bacterial growth and extends reconstituted shelf life to 4 weeks when kept refrigerated.
Order AOD-9604 — ships to Dagbao I
COA-verified · International tracking · Research grade
All use of AOD-9604 in Dagbao I or anywhere constitutes research use — this compound is not approved for therapeutic human application, and all handling should comply with standard research safety practices. Temperature excursions — even brief warming above recommended storage temperature — can compromise product integrity without detectable changes to appearance; always maintain cold chain and work with cold-shipped material. Endotoxin testing in the AOD-9604 COA is absolutely required — gram-negative bacterial endotoxins can trigger severe inflammatory responses at trace quantities, and no pricing advantage justifies skipping this verification. The research literature on AOD-9604 should be studied thoroughly before beginning any research — study designs, dosing ranges, and outcome measures vary significantly and not all findings translate directly.
Frequently Asked Questions
What is AOD-9604?
AOD-9604 is a synthetic peptide analogue of the C-terminal fragment of human growth hormone (amino acids 177-191), with an additional tyrosine residue at the N-terminus. It has been studied for fat metabolism effects, specifically lipolysis stimulation and lipogenesis inhibition, without the IGF-1-stimulating effects of full-length GH. It has undergone clinical trials for obesity treatment.
What is the clinical trial history of AOD-9604?
AOD-9604 has undergone multiple Phase II clinical trials for obesity treatment by Metabolic Pharmaceuticals in Australia. The trials showed safety and tolerability but mixed efficacy results for weight loss. It holds GRAS (Generally Recognized As Safe) status from the FDA for food use, which is unusual for research peptides.
How does AOD-9604 differ from growth hormone?
AOD-9604 contains only the fat-metabolism-relevant fragment of growth hormone (the C-terminal region) without the IGF-1-stimulating N-terminal domain. This means it targets fat cells' beta-adrenergic receptors for lipolytic effects without producing the anabolic IGF-1 signaling associated with full-length GH.
